GLP-1s are linked to a higher risk for osteoporosis, gout, and osteomalacia in people with type 2 diabetes and obesity, new research suggests, though an additional study also points to better ...

GLP-1 drugs — including Ozempic and Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according to ...

According to the Gallup National Health and Well-Being Index, 37% of U.S. adults now report obesity, down from 39.9% three ...

Health expert discusses the side effects of popular GLP-1s. 'We know that consumers' behavior changes': McDonald's prepares ...

As more patients take GLP-1 medications, it’s common for patient questions to arise about how alcohol consumption may affect ...

In studies published so far, GLP-1 receptor agonists appear to be beneficial for the treatment of glaucoma, according to a review published in Cureus.“GLP-1 RAs exert both protective and adverse ...

Recent studies show GLP-1s tied higher osteoporosis risk, with variations by diabetes status and weight changes in large patient datasets.

Two studies examining the use of glucagon-like peptide-1 receptor agonists, including semaglutide, have found short- and long-term associations in orthopedic postoperative outcomes and general ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of Type 2 diabetes drugs that improves blood sugar and may also lead to weight loss. These drugs — including ...